| ID | 1291 |
| Name of the vaccine | BK1310 |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 2 to 42 months |
| Description of the vaccine | DPT-IPV-Hib vaccine. |
| Name of the manufacturer | Mitsubishi Tanabe Pharma Corporation |
| Name of the manufacturing country | Japan |
| Year of manufacture | 2020 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | 0.5 ml, 3 times with the 3-8 weeks intervals, then after 6-13 months. |
| Mechanism of action | NA |
| Route of administration | Subcutaneous |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For diphtheria, tetanus, poliomyelitis and bacterial meningitis. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT03891758 |
| Reference | https://www.centerwatch.com/clinical-trials/listings/108627/immunization;-infection-phase-3-study-bk1310/ |
| Other name | NA |
| Additional Links | NA
|